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Objectives: We aimed to describe the burden, epidemiology and outcomes of co-26 
infections and superinfections occurring in hospitalised patients with COVID-19.  27 
Methods: Observational cohort study of all consecutive patients admitted ≥ 48 hours 28 
to Hospital Clinic of Barcelona for COVID-19 (February 28
th
 - April 22
nd
, 2020) who are 29 
currently discharged or dead. We describe demographic, epidemiologic, laboratory, 30 
and microbiologic results, as well as outcome data retrieved from electronic health 31 
records.  32 
Results: Of a total of 989 consecutive patients with COVID-19, 72 (7.2%) had 88 other 33 
microbiologically confirmed infections: 74, bacterial; 7, fungal and 7, viral. Community-34 
acquired co-infection at COVID-19 diagnosis was uncommon (31 out of 989, 3.1%) and 35 
mainly caused by Streptococcus pneumoniae and Staphylococcus aureus. A total of 51 36 
hospital-acquired bacterial superinfections, mostly caused by Pseudomonas 37 
aeruginosa and Escherichia coli, were diagnosed in 43 (4.7%) patients, with a mean 38 
time from hospital admission to superinfection diagnosis of 10.6 (SD 6.6) days. Overall 39 
mortality was 9.8% (97/989). Patients with community-acquired co-infections and 40 
hospital-acquired superinfections presented with worse outcomes.  41 
Conclusions: Co-infection at COVID-19 diagnosis is uncommon.  Few patients 42 
developed superinfections during hospitalisation. These findings are quite differential 43 
when compared with those of other viral pandemics. As it relates to hospitalised 44 
patients with COVID-19, such findings could prove essential in defining the role of 45 




The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has 48 
presented a formidable medical challenge before health systems and clinicians [1–4]. 49 
With >250,000 cases diagnosed by 9 July, Spain has particularly suffered from this 50 
pandemic [5].  Many decisions have been made with limited clinical experience and 51 
scientific evidence, especially as it concerns treatments for patients hospitalised with 52 
the coronavirus disease 2019 (COVID-19). One such clinical decision is that regarding 53 
the use of antibiotic therapy in patients with COVID-19. Bacterial, especially 54 
Streptococcus pneumoniae and Staphylococcus aureus, and viral or fungal co-infections 55 
are common complications described as arising in other pandemics caused by 56 
influenza viruses [6–9]; however, information concerning incidence of such co-57 
infections in patients with COVID-19 has been scarce. Similarly, information related to 58 
COVID-19 superinfections is lacking, although it is essential to rational antimicrobial 59 
stewardship.  60 
We aimed to describe the burden and epidemiology of community-acquired co-61 
infections and hospital-acquired superinfections in a large cohort of all consecutive 62 
hospitalised patients admitted with COVID-19 for 48 hours or more in Barcelona, who 63 
are either currently discharged or dead. The impact of co-infections and 64 




Study design and patients 67 
This observational cohort study was performed at Hospital Clinic in Barcelona (Spain), 68 
a 700-bed university centre that provides broad and specialised medical, surgical, and 69 
intensive care for an urban population of 500,000 adults (>18 years old). All patients 70 
admitted with COVID-19 for ≥48 hours between 28 February and 22 April 2020, and 71 
who are currently discharged alive or had died during hospitalisation, were included. 72 
All patients had a diagnosis of COVID-19 confirmed by real-time reverse transcription 73 
polymerase chain reaction (RT-PCR) testing performed on nasopharyngeal throat swab 74 
specimens, and/or by fulfilling  clinical diagnostic criteria provided during the 75 
pandemic peak for SARS-CoV-2. These criteria comprised the presence of any of the 76 
following respiratory symptoms, including sore throat, congestion, cough, dyspnoea, 77 
new loss of taste and/or smell, as well as uni- or bilateral interstitial infiltrates in the 78 
chest X-ray. The Institutional Ethics Committee of Hospital Clinic of Barcelona 79 
approved the study and due to the nature of the retrospective data review, waived the 80 
need for informed consent from individual patients (HCB/2020/0273). 81 
 82 
Data collection and outcomes 83 
For all patients hospitalised with COVID-19, data concerning demographics (age, 84 
gender), epidemiology, comorbidities, laboratory tests, microbiological results (blood 85 
and urine cultures, respiratory samples, urinary antigen tests and antimicrobial 86 
susceptibility), treatment and outcomes (intensive care unit [ICU] admission, length of 87 
hospital stay, and mortality) were collected directly from electronic health records 88 
(EHR) as previously described [10]. The EHR of all patients with positive microbiologic 89 
 
 
results were reviewed by one of our researchers (CGV, EMG or CC) to assess clinical 90 
significance.  91 
 92 
Procedures 93 
Investigation of bacterial, viral and fungal pathogens in blood, normally sterile fluids, 94 
sputum and other samples was performed with standard microbiologic procedures 95 
upon hospital admission, as requested by the attending physician. Bacterial respiratory 96 
infection was diagnosed in patients with 1 or more positive cultures of respiratory 97 
pathogens obtained from blood, pleural fluids, good-quality sputum (>25 98 
polymorphonuclear leukocytes and <25 epithelial cells) and bronchoalveolar lavage, 99 
and/or a positive urinary antigen test. S. pneumoniae antigen in urine was detected 100 
with a rapid STANDARD F S. pneumoniae Ag FIA assay (SD Biosensor, Inc. Republic of 101 
Korea). Specific, rapid RT-PCR testing was used for influenza A and B viruses, as well as 102 
respiratory syncytial virus (RSV) diagnosis (cobas Liat System, Roche). Multiplex PCR 103 
testing (Flow System, Roche) was also used for influenza viruses: A, B and C; 104 
parainfluenza: 1,2,3 and 4; and metapneumovirus diagnosis.   105 
 106 
Definitions 107 
Bloodstream infection (BSI) was defined as the growth of a non-skin flora commensal 108 
from ≥ 1 blood culture. To define a BSI as that caused by a common skin coloniser such 109 
as coagulase-negative staphylococci or Corynebacterium, we required ≥2 blood 110 
cultures drawn from different sites and a clinical evaluation from one of our 111 
researchers (CGV or EMG). We then considered the clinical significance of such BSI. 112 
Urinary infection was defined as the growth of a bacterium or fungus in a urine culture 113 
 
 
from a patient with clinical symptoms and/or the consideration of such urinary 114 
infection as clinically significant by one of our researchers (CGV or EMG). Aspergillus 115 
tracheobronchitis was defined as the isolation of Aspergillus species from 116 
endobronchial specimens of intubated patients with purulent secretions, as well as 117 
clinical validation from one of our researchers (CGV or CC).   118 
All of these clinically-indicated infections were categorised as co-infections or 119 
superinfections. If diagnosis was at onset or within the first 24h of COVID-19 hospital 120 
admission, these infections were defined as community-acquired co-infections. If 121 
diagnosis occurred ≥48h of admission for COVID-19, these infections were defined as 122 
hospital-acquired superinfections. 123 
 124 
Statistical analysis 125 
For the purpose of the present study, a descriptive analysis of clinical and laboratory 126 
tests was performed. Continuous and categorical variables were presented as median 127 
(interquartile range [IQR]) and absolute number (percentage), respectively. We used 128 
the Mann-Whitney U-test, χ2 test and Fisher’s exact test to compare differences 129 
between patients who had other infections and those who did not. Significance was a 130 
p-value <0.05. Statistical analyses were performed with Microsoft SPSS-PC+, version 131 




We assessed 989 consecutive adults with COVID-19 at our hospital who had either 134 
been discharged or had died during the study period. Of these, 552 (55.8%) were male 135 
and the median age was 62 (IQR 48-74) years. Main patient characteristics by groups 136 
are shown in Table 1. Table 2 details the number of microbiology tests requested by 137 
attending physicians and positive results with clinical significance. A total of 88 non-138 
COVID-19 infections were documented in 72 (7.3%) patients: 74, bacterial; 7, fungal; 139 
and 7, viral. A total of 74 bacterial infections were diagnosed in 61 of 88 patients (3 140 
infections in one patient, 2 in 12 individual patients and 1 in every remaining patient). 141 
The most common bacteria isolated were S. pneumoniae (12 cases); S. aureus, 12; 142 
Pseudomonas aeruginosa, 10; Escherichia coli, 7; and Klebsiella pneumoniae, 6. 143 
 144 
Community-acquired co-infections 145 
Overall, 31 of 989 (3.1%) patients had 37 community-acquired co-infections. Thirty 146 
community-acquired bacterial co-infections were documented in 25 (2.5%) patients. 147 
Specifically, bacterial pneumonia co-infection was documented in 21 (2.1%) patients at 148 
COVID-19 diagnosis. Two of these co-infections were with different bacteria. S. 149 
pneumoniae (one patient had a Moraxella catarrhalis co-infection) and S. aureus (one 150 
patient had a Haemophilus influenzae co-infection) were the most common bacteria in 151 
this scenario. Two patients had infections caused by methicillin-resistant S. aureus. 152 
Diagnosis of community-acquired bacterial co-infection was performed with one or 153 
more of the following tests: urinary antigen test in 12 cases; good quality sputum, 2 154 
and blood cultures, 1. 155 
 
 
Viral community-acquired co-infection was detected in 7 of 989 (0.6%) patients, of 156 
whom one presented with bacterial co-infection as well: 4 cases of influenza A virus 157 
co-infection; 1, influenza B virus; 1, respiratory syncytial virus and 1, herpetic disease. 158 
Two of these 7 (28.6%) patients, with influenza A and influenza B virus co-infections, 159 
respectively, died.  160 
 161 
Hospital-acquired superinfections 162 
A total of 51 hospital-acquired superinfections were documented in 43 patients. Of 163 
these, 44 were bacterial and diagnosed in 38 (3.8%) patients. The mean time from 164 
hospital admission to superinfection diagnosis was 10.6 (SD 6.6) days. Of these 44 165 
superinfections, 25 (56.8%) occurred in patients admitted to the ICU. The most 166 
frequently isolated microorganisms were P. aeruginosa (8 cases); E. coli, 6; Klebsiella 167 
spp., 5 and S. aureus, 5. The most common hospital-acquired superinfections were 168 
those of the respiratory tract and bacteremia. Multidrug-resistant Gram-negative 169 
bacteria (MDR-GNB) were isolated in 7 patients: 3, MDR-P. aeruginosa infection; 2, 170 
Extended-Spectrum ß-Lactamase (ESBL)-E. coli; and 2, ESBL-K. pneumoniae. Table 3 171 
details epidemiology of all bacterial co-infections and superinfections.  172 
Seven of 989 (0.7%) patients had fungal hospital-acquired superinfections: 3 cases 173 
caused by Aspergillus fumigatus and 4, Candida albicans. Two patients were diagnosed 174 
with bacterial and fungal superinfections. All three patients with tracheobronchitis 175 
caused by A. fumigatus had prior lung disease and a median age of 75 (IQR 70-75) 176 
years. These patients were also critically ill and received mechanical ventilation 177 
support and high corticosteroid dosage. In this series of patients, only one died. 178 
Patients with C. albicans superinfection had the following clinical syndromes: two 179 
 
 
cases of candidemia in an ICU setting; one case of a nosocomial urinary tract infection 180 
related to a urinary catheter and one case of a complicated intra-abdominal infection. 181 
Two patients died.  182 
Outcomes 183 
Overall mortality for patients hospitalised with COVID-19 for 48 hours or more was 184 
9.8% (97 of 989 patients). Table 1 details the most important outcomes in hospitalised 185 
patients with COVID-19 who present without infection, those with community-186 
acquired co-infection and those with hospital-acquired superinfection. Remarkably, 187 
patients with community-acquired co-infections were admitted to the ICU more 188 
frequently. In comparison to those without infection, patients with hospital-acquired 189 




We present a large series of patients from a Spanish region dramatically affected by 192 
the COVID-19 pandemic, focusing on describing community-acquired co-infections and 193 
hospital-acquired superinfections in these patients. Remarkably, bacterial pneumonia 194 
co-infection in patients hospitalised for COVID-19 was lower when compared with co-195 
infections occurring in patients suffering from other respiratory virus infections such as 196 
influenza H1N1 or influenza H3N2 [6,8,11,12]. A minority of patients had bacterial or 197 
fungal superinfections and co-infections caused by other viruses.  198 
Our results are concordant with a recent review that summarised nine studies 199 
reporting data concerning co-infections in patients with COVID-19. An 8% rate for 200 
bacterial and fungal co-infections was described [13]. In a recent letter, Kim et al 201 
reported relatively low rates (ranging from 0% for most pathogens to 12% in 202 
rhinovirus/enterovirus) of co-infections between SARS-CoV-2 and other respiratory 203 
pathogens [14]. Bacterial community-acquired pneumonia co-infections documented 204 
in our cohort have been especially low. Considering the high number and severity of 205 
bacterial co-infections previously reported in patients with influenza H1N1 and H3N2 206 
[6–9], upon arrival of the COVID-19 pandemic, our hospital protocol recommended the 207 
initiation of antibiotic therapy for all hospitalised patients with COVID-19. Experience 208 
acquired within the first, few weeks led us to reconsider this approach, so as to 209 
administer empiric antibiotic therapy solely to patients admitted for COVID-19 and 210 
who present with a chest x-ray suggestive of bacterial infection, need for direct ICU 211 
admission or severe immunocompromised condition. Our results support the 212 
avoidance of antibiotic therapy in most patients hospitalised for COVID-19. The reason 213 
 
 
for which bacterial co-infections are quite low in patients with COVID-19 is unknown; it 214 
is tempting to speculate that some immunological facts like macrophage 215 
hyperactivation play a role. Nonetheless, when bacterial co-infection is suspected, we 216 
recommend an antibiotic approach with optimal S. aureus coverage such as ceftaroline 217 
or ceftriaxone/cefazolin plus levofloxacin in areas with low MRSA prevalence.   218 
Frequency of hospital-acquired superinfections remained low despite the fact that 219 
many patients were undergoing severe immunosuppressant treatments. Some factors 220 
may provide an explanation for that observation, including empiric antibiotic use, 221 
isolation measures or host macrophage activation. Further, the lack of additional 222 
microbiologic tests after SARS-CoV-2 was detected may have also contributed. Further 223 
studies will be needed to elucidate the role of each measure in decreasing 224 
superinfections. Superinfections have been mainly related with ICU admission, 225 
especially with the use of mechanical ventilation and catheters; expected 226 
epidemiology linked closely with predominant hospital flora. In our study, the rate of 227 
MDR infections was relatively low due to the possible impact of COVID-19 isolation 228 
measures precluding horizontal transmission among patients.  229 
Aspergillosis complicating COVID-19 was clinically quite different and not as frequent 230 
as that observed in patients with influenza [12,13]. In patients with COVID-19, 231 
aspergillosis usually manifested as tracheobronchitis, especially in association with 232 
patients with prior lung disease, prolonged mechanical ventilation and high 233 
immunosuppressor dosage. In the opinion of this study’s authors, this fact may also be 234 
in part related to the different immunologic dysfunction in influenza and COVID-19 235 
infections [11,13,15]. Macrophages are the key host cell in fighting Aspergillus spp. due 236 
 
 
to their involvement in Aspergillus spores recognition [16]. Patients admitted with 237 
COVID-19 also had Candida spp. superinfections mainly related with parenteral 238 
nutrition and urinary catheters.     239 
Anecdotal cases of co-infections during SARS-CoV-2 and other virus infections have 240 
been previously reported [16–19]. Our results support that respiratory virus 241 
community-acquired co-infection is relatively uncommon in hospitalised patients with 242 
COVID-19. However, viral co-infections could lead to severe diseases, and this study 243 
was conducted in a mostly non-influenza season (incidence could vary in fall/winter).   244 
Overall mortality in the cohort of patients hospitalised ≥48 hours was 9.8%. We found 245 
that patients with other infections had worse outcomes, prolonged length of hospital 246 
stay, higher rates of ICU admission and increased mortality. These finding are in 247 
agreement with previous studies, which documented an association between co-248 
infection in respiratory virus pandemics and poor prognosis [6–8]. However, this is 249 
unadjusted to baseline patients’ characteristics and cannot be completely attributed to 250 
co-infection and/or superinfections. 251 
The strengths of this study comprise the large number of patients included, as well as 252 
the clear, complete collection of clinical and microbiologic data. However, our study 253 
does have some major limitations that should be acknowledged. First, this is a 254 
retrospective study reporting clinically significant, microbiologically documented 255 
infections. However, no systematic testing for co-infections was performed, and it is 256 
possible that either some attending physicians did not order microbiologic tests for 257 
their patients or some patients may have had co-infections or superinfections not 258 
documented by performed microbiologic tests. A concern held among our team is 259 
 
 
whether initial challenges arising during the management of patients with COVID-19 260 
potentially decreased the number of requests for microbiologic tests to rule out other 261 
infections. Notwithstanding, infection rates reported in our study remained low, even 262 
in patients in whom urinary antigen testing or other types of test had been performed. 263 
Second, we described a cohort of patients currently discharged or dead. Some patients 264 
with severe COVID-19 infection that required ICU admission, mechanical ventilation 265 
and prolonged length of hospital stay remain hospitalised. It is conceptually easy to 266 
believe that superinfection is higher in this population. Third, respiratory RT-PCR 267 
techniques used were limited to the virus. PCR testing for the detection of atypical 268 
pathogens was not performed in our patients. Additionally, and as mentioned prior, 269 
we initially treated all hospitalised patients with antibiotics within the first, few weeks, 270 
for which the impact of such practice in preventing superinfections remains unknown. 271 
That stated, the first four limitations might underestimate the frequency of co-272 
infections or superinfections in patients with COVID-19. Lastly, as this study was 273 
conducted at a single centre, there may have been influence when describing 274 
nosocomial infections. Frequency and microbiologic epidemiology may also vary 275 
significantly according to different geographical contexts.  276 
In conclusion, bacterial, fungal and viral co-infections and superinfections in 277 
hospitalised patients with COVID-19 are low; however, when present, they may cause 278 
severe diseases with worse outcomes. S. pneumoniae and S. aureus are the most 279 
common pathogens to cause community-acquired pneumonia co-infections. In our 280 
area, P. aeruginosa and E. coli were frequent bacteria that caused hospital-acquired 281 
superinfections. Our findings are important when defining the role of empiric 282 
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Median age, years (IQR) 61 (48-74) 63 (54.5-74) 0.671 67 (55.75-74.25) 0.006 
Male sex (%) 510 (55.6) 18 (58.1) 0.956 26 (60.5) 0.822 
Comorbidities      
Hypertension (%) 167 (18.2) 7 (22.6) 0.537 7 (16.3) 0.748 
Diabetes mellitus (%) 89 (9.7) 7 (22.6) 0.019 7 (16.3) 0.160 
Chronic heart disease (%) 122 (13.3) 9 (29) 0.013 7 (16.3) 0.576 
              Chronic lung disease (%) 95 (10.4) 6 (19.4) 0.110 7 (16.3) 0.218 
              Chronic renal disease (%) 47 (5.1) 8 (25.8) <0.001 6 (14) 0.013 
Cancer (%) 77 (8.4) 1 (3.2) 0.259 8 (18.6) 0.021 
Inflammatory markers at onset      
Median C-reactive protein 
(IQR) 
7.06 (3.31-13.29) 6.76 (3.20-9.79) 0.714 11.78 (5.55-17.87) 0.012 
Median ferritin (IQR) 544 (249.5-1100) 208 (154-431.5) 0.042 797 (296-1743) 0.575 
Median lymphocyte count 
(IQR) 
0.9 (0.6-1.2) 0.8 (0.6-1.1) 0.892 0.783 (0.5-1.1) 0.088 
Median lactate 
dehydrogenase (IQR) 
287 (233-372) 264 (221-377.5) 0.477 311.5 (247.5-471-8) 0.193 
Treatment at onset      
Lopinavir-ritonavir (%) 732 (79.8) 27 (87.1) 0.227 35 (81.4) 0.802 
Hydroxychloroquine (%) 799 (87.1) 29 (93.5) 0.225 40 (93) 0.186 
Azythromicin (%) 751 (81.9) 26 (83.9) 0.779 36 (83.7) 0.761 
Remdesivir (%) 39 (4.3) 0 (0) 0.226 2 (4.7) 0.559 
Ceftriaxone (%) 528 (57.6) 24 (77.4) 0.028 32 (74.4) 0.029 
Ceftaroline (%) 26 (2.8) 2 (6.5) 0.232 5 (11.6) 0.001 
Immunomodulatory treatment      
Tocilizumab (%) 200 (21.8) 5 (16.1) 0.450 16 (37.2) 0.018 
Methylprednisolone (%) 238 (26) 9 (29) 0.701 25 (58.1) <0.001 
Dexamethasone (%) 23 (2.5) 4 (12.9) 0.01 8 (18.6) <0.001 
Median length of hospital stay (IQR) 9 (5-15) 8 (4.5-11.5) 0.565 20 (11-27.75) <0.001 
Intensive Care Unit (ICU) admission 
(%) 
109 (11.9) 8 (25.8) 0.02 29 (67.4) <0.001 
Median Length of ICU admission 
(IQR) 
3 (1-10) 3 (0-9) 0.888 5 (0.5-20) 0.095 
Death (%) 86 (9.4) 5 (16.1) 0.21 8 (18.6) 0.047 
Two patients with community-acquired co-infection developed hospital-acquired superinfections.  
*Comparison of patients without infection versus patients with community-acquired co-infection. 
**Comparison of patients without infection versus patients with hospital-acquired superinfection. 
















*5 patients underwent PCR testing for Influenza C, human Metapneumovirus and Parainfluenza 1, 2, 3 and 4. All were negative. 
Test 
Number of patients 
with positive 
results/total patients 
Number of patients 
with positive results/ 
tested patients 
Number of tests with 
positive results/total 
tests 
Blood cultures 16/989 (1.6%) 16/267 (5.9%) 37/680 (5.5%) 
Urine cultures 19/989 (1.9%) 19/337 (5.6%) 19/717 (2.6%) 
Respiratory samples (non-
COVID) 
25/989 (2.5%) 25/252 (9.9%) 23/845 (2.7%) 
Pneumococcal urinary 
antigen 
12/989 (1.2%) 12/230 (5.2%) 12/234 (5.1%) 
Influenza A PCR 4/989 (0.4%) 4/248 (1.6%) 5/252 (1.9%) 
Influenza B PCR 2/989 (0.2%) 2/250 (0.8%) 2/255 (0.8%) 
Respiratory syncytial virus 
PCR 
1/989 (0.1%) 1/251 (0.4%) 1/256 (3.9%) 
Other respiratory virus 
PCR* 
0/989 0/5 0/16 
Table 3. Detailed epidemiology of microbiological documented bacterial infections in 
patients hospitalized with COVID-19. 
 
Bacterial co-infection* N=74 (%) 
Infections at COVID-19 diagnosis  30/74 (40.5) 
Community-acquired pneumonia co-infections 21/30 (70) 
        S. pneumoniae 12/21 (57.1) 
S. aureus 6/21 (28.6) 
H. influenzae 2/21 (9.5) 
M. catarrhalis 1/21 (4.8) 
      Lower respiratory co-infection in patients with 
bronchiectasis 
2/30 (6.6) 
P. aeruginosa 2/2 (100) 
Concurrent urinary tract infection 7/30 (23.3) 
E. coli 1/7 (14.2) 
K. pneumoniae 1/7 (14.2) 
E. faecium 1/7 (14.2) 
P. mirabilis  1/7 (14.2) 
C. koseri 1/7 (14.2) 
S. aureus  1/7 (14.2) 
Hospital-acquired superinfections complicating 
patients admitted for COVID-19 
44/74 (59.5) 
Ventilator-associated pneumonia  11/44 (25) 
S. aureus 4/11 (36.4) 
P. aeruginosa 3/11 (27.3) 
S. maltophilia 2/11 (18.2) 
K. pneumoniae 1/11 (9) 
S. marcescens 1/11 (9) 
       Hospital-acquired pneumonia  4/44 (9) 
S. aureus 1/4 (25) 
P. aeruginosa 1/4 (25) 
S. maltophilia 1/4 (25) 
K. pneumoniae 1/4 (25) 
Bacteremia 16/44 (36.3) 
Coagulase-negative staphylococci 7/16 (43.7) 
P. aeruginosa  3/16 (18.7) 
E. faecium 3/16 (18.7) 
E. coli 2/16 (12.5) 
S. anginosus 1/16 (6.2) 
Urinary tract infection 12/44 (27.3) 
E. coli 4/12 (33.5) 
K. pneumoniae 3/12 (25) 
E. faecalis 2/12 (16.7) 
E. faecium  1/12 (8.3) 
P. aeruginosa 1/12 (8.3) 
S. marcescens 1/12 (8.3) 
Polymicrobial intra-abdominal infection 
(E. coli, E. faecium, E. faecalis) 
1/44 (2.3) 
*Some patients had more than one bacterial infection. 
 
